We can control the development of metabolic disease by controlling the abnormally elevated levels of liver proteins during the disease, including some ANGPTL family proteins, fetuin-A, heparin, etc. This would control the development of metabolic disease by improving insulin sensitivity and maintaining lipid homeostasis to suppress systemic inflammation and IR. This evidence concerns the gene INS and metabolic disease.